Related Experiment Videos
Plasma homocysteine and inflammation in elderly patients with cardiovascular disease and dementia
G Ravaglia1, P Forti, F Maioli
1Department of Internal Medicine, Cardioangiology, and Hepatology, University Hospital S. Orsola-Malpighi, Bologna 40138, Italy.
Insights
Elevated total homocysteine (tHcy) and C-reactive protein (CRP) are linked in older adults with comorbidities, suggesting poor health rather than specific vascular inflammation.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Neurology
Background:
- Elevated plasma total homocysteine (tHcy) is implicated in cardiovascular diseases (CVD) and dementia.
- Serum C-reactive protein (sCRP) is a marker for low-grade inflammation, but its association with tHcy is unclear.
- Comorbidities like chronic obstructive pulmonary disease (CPOD) and peptic ulcer (PU) are common in older adults.
Purpose of the Study:
- To investigate the association between plasma tHcy and sCRP in older adults.
- To examine if this association differs in healthy aging, CVD, and dementia.
- To determine if comorbid CPOD or PU modifies the tHcy-sCRP relationship.
Main Methods:
- Cross-sectional study of 627 individuals aged 65+.
- Participants included healthy controls, CVD patients (with and without comorbidities), and dementia patients.
- Statistical analysis controlled for confounders like age, sex, socio-demographic status, and vascular risk factors.
Main Results:
- A significant positive association between plasma tHcy and sCRP was observed in CVD patients with comorbidities (CVD+/comorbidity+) and dementia patients (p=0.001).
- This association was independent of several potential confounders.
- No significant association was found in healthy controls or CVD patients without comorbidities (CVD+/comorbidity-).
Conclusions:
- The link between plasma tHcy and sCRP in older adults appears to be an indicator of general poor health, particularly in the presence of comorbidities.
- This association is not a specific correlate of vascular inflammation in the studied groups.
- Findings suggest a broader health status marker rather than a direct link to vascular inflammation mechanisms.
Abstract:
Increased levels of plasma total homocysteine (tHcy) may play a role in both cardiovascular diseases (CVD) and old-age dementias via enhancement of vascular inflammation. However, the association between plasma tHcy and serum C-reactive protein (sCRP), taken as a marker of low-grade inflammation, is still uncertain. We investigated this association in normal aging, CVD, and dementia, and examined whether it was modified by the presence of two major comorbid diseases of older age: chronic obstructive pulmonary disease (CPOD) and peptic ulcer (PU). Six hundred-twenty-seven individuals aged > or = 65 yr (74+/-7 yr) were selected for this study: 373 healthy controls; 160 patients with CVD but no evidence of comorbid diseases (CVD+/comorbidity-); 46 patients with CVD and concurrent CPOD and/or PU (CVD+/comorbidity+); and 48 patients with dementia. A positive association between plasma tHcy and serum CRP, independent of several confounders (socio-demographic status, known tHcy and sCRP determinants, inflammation markers, traditional vascular risk factors), was found for CVD+/comorbidity+ (p=0.001; not affected by dementia type) and dementia (p=0.001; not affected by dementia type), but not for CVD+/comorbidity- and controls. The results suggest that the association between plasma tHcy and sCRP is more an aspecific reflection of poor health than a specific correlate of vascular inflammation.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacodynamics in Geriatric Patients: Effects of Age
Dementia l: Introduction
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Atherosclerosis III: Management